3D Medicines Inc
01244
Company Profile
Business description
3D Medicines Inc is a commercial-stage biopharmaceutical company engaged in the research and development of oncology therapies for cancer patients, especially those who require long-term care. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.
Contact
No. 3 and No. 5, Laiyang Road
Shandong
Qingdao
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
191
Stocks News & Analysis
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,995.80 | 19.60 | -0.22% |
CAC 40 | 7,861.96 | 4.60 | 0.06% |
DAX 40 | 24,262.22 | 44.85 | 0.19% |
Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
FTSE 100 | 9,136.94 | 0.62 | 0.01% |
HKSE | 24,799.91 | 377.02 | -1.50% |
NASDAQ | 21,129.67 | 31.38 | 0.15% |
Nikkei 225 | 41,102.12 | 447.42 | 1.10% |
NZX 50 Index | 12,823.74 | 32.23 | -0.25% |
S&P 500 | 6,362.90 | 7.96 | -0.12% |
S&P/ASX 200 | 8,740.20 | 16.20 | -0.19% |
SSE Composite Index | 3,580.98 | 34.73 | -0.96% |